Batistaki Chrysanthi, Vagdatli Kyriaki, Tsiotou Adelais, Papaioannou Alexandra, Pandazi Aggeliki, Matsota Paraskevi
Task Force of the Hellenic Society of Anaesthesiology for the Management of Neuromuscular Blockade, National and Kapodistrian University of Athens, "Attikon" University Hospital, Athens, Greece.
2 Department of Anaesthesiology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" University Hospital, Athens, Greece.
J Anaesthesiol Clin Pharmacol. 2019 Apr-Jun;35(2):202-214. doi: 10.4103/joacp.JOACP_195_18.
The aim of this study was to investigate the current status of clinical practice regarding neuromuscular blocking drugs and their antagonists in Greece.
This is a multicenter survey, including a questionnaire based on previous studies, which was translated and modified by a Task Force of the Hellenic Society of Anaesthesiology. It was completed on a web-based database after invitation via e-mail and was left online for a period of 2 months.
A total of 1,100 questionnaires were sent, with a response rate of 7.9%. 13.7% stated that they do not use neuromuscular monitoring. Rocuronium was most commonly used for intubation ["often" stated by 19 (21.8%) and "very often" by 62 (71.2%)], followed by cis-atracurium, atracurium, and succinylcholine. Neostigmine and sugammadex were both used, with reversal not always administered by 23 (26.4%). Both agents were mostly used at fixed doses and not calculated based on TOF monitoring or body weight. Sugammadex was preferred in special patient groups and in operations of short duration. Reversal was most often administered based on clinical signs of neuromuscular recovery rather than objective monitoring. A significant percentage of respondents used an inadequate TOF ratio for extubation [37 (43.2%) used a TOF ratio <90%]. The reported incidence of observed residual neuromuscular blockade (RNMB) was 44.8%.
Great variability was observed in Greek clinical practice regarding the use of neuromuscular blockade, which indicates serious issues that must be addressed. The needs for educating anesthesia providers and developing official guidelines are obvious in order to improve patient outcomes.
本研究旨在调查希腊在神经肌肉阻滞药物及其拮抗剂临床应用方面的现状。
这是一项多中心调查,采用基于既往研究的问卷,由希腊麻醉学会特别工作组进行翻译和修改。通过电子邮件邀请后,在基于网络的数据库上完成问卷,并在网上留存2个月。
共发放1100份问卷,回复率为7.9%。13.7%的受访者表示他们不使用神经肌肉监测。罗库溴铵最常用于插管(19人[21.8%]表示“经常”使用,62人[71.2%]表示“非常经常”使用),其次是顺式阿曲库铵、阿曲库铵和琥珀酰胆碱。新斯的明和舒更葡糖均有使用,23人(26.4%)并非总是进行肌松拮抗。两种药物大多采用固定剂量,而非根据强直刺激后计数(TOF)监测或体重计算。舒更葡糖在特殊患者群体和短时间手术中更受青睐。肌松拮抗大多基于神经肌肉恢复的临床体征而非客观监测进行。相当比例的受访者在拔管时使用的TOF比值不足[37人(43.2%)使用的TOF比值<90%]。报告的残余神经肌肉阻滞(RNMB)观察发生率为44.8%。
在希腊临床实践中,神经肌肉阻滞的使用存在很大差异,这表明存在必须解决的严重问题。为改善患者预后,显然需要对麻醉人员进行培训并制定官方指南。